Bannerbild German Brest Group

Effect of BRCA1/2 Status on Response to Neoadjuvant Carboplatin in TNBC

17.08.2017

Our paper on mutations analysis in the Geparsixto TNBC-Arm was discussed at ASCO-News.

News

  • 05.07.2017  PALOMA-3 Results published

    Palbociclib Combined with Fulvestrant in PremenopausalWomen with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results

    Mehr ...
  • 03.02.2017  How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?

    Prof. Loibl and Prof. Denkert discuss "How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?" in the current JCO Editorial.

    Mehr ...
  • GBG Jahrestreffen und AGO Mamma State of the Art

    GBG Jahrestreffen und AGO Mamma State of the Art

    Vom 2. bis 3. März 2017 findet das GBG Jahrestreffen 2017 und am 4. März das AGO Mamma State of the Art-Meeting statt. Weitere Informationen finden Sie hier.

    Mehr ...
  • 31.01.2017  Young Investigator Award

    Young Investigator Award

    Die GBG vergibt einen Reise zum ESMO in Madrid in 2017 für junge Wissenschaftler. Bewerbung ab sofort möglich.

    Mehr ...
  • 08.12.2016  The Lancet - Breast Cancer Series 2016

    The introduction of targeted therapies has profoundly changed the course of some subtypes of breast cancer—but many challenges remain. The Lancet’s 2016 Series on breast cancer discusses the most recent advances in the three most common breast cancer subtypes. The first pair of papers focus on the treatment of advanced oestrogen-receptor-positive and HER2-positive breast cancers, while the third describes how an improved understanding of molecular alterations in the heterogeneous and hard-to-treat triple-negative breast cancer may lead to more refined and more effective therapy. http://www.thelancet.com/series/breast-cancer-2016

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd